Pharmacare News Bulletins
Nova Scotia Pharmacare
Pharmacare News Bulletins
The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.
Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.
Latest Issues
February Bulletin Vol. 19 – 01
New Exception Status Benefits: Procysbi (cysteamine bitartrate), Nucala (mepolizumab), Ocaliva (obeticholic acid), Ravicti (glycerol phenylbutyrate), Taltz (ixekizumab) Criteria Update: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Inflectra and Remicade (infliximab), Simponi (golimumab)
Latest Issue
February Bulletin Vol. 19 – 01
New Exception Status Benefits: Procysbi (cysteamine bitartrate), Nucala (mepolizumab), Ocaliva (obeticholic acid), Ravicti (glycerol phenylbutyrate), Taltz (ixekizumab) Criteria Update: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Inflectra and Remicade (infliximab), Simponi (golimumab)
Previous Pharmacists' Bulletins
Complete Volume Eighteen 2018 (PDF)
Complete Volume Seventeen 2017 (PDF)
Complete Volume Sixteen 2016 (PDF)
Previous Physicians' Bulletins
Complete Volume Seventeen 2018 (PDF)
Complete Volume Seventeen 2017 (PDF)
Complete Volume Sixteen 2016 (PDF)